A Multicenter, Double-blind, Randomized, Parallel-group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50mg qd to Placebo as add-on Therapy to Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy.
Phase of Trial: Phase III
Latest Information Update: 31 May 2014
At a glance
- Drugs Vildagliptin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis
- 07 Jun 2017 Biomarkers information updated
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.